Panacea Biotec bags US $127.30 mn for supply of Pentavalent Vaccine

UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027

ICON selected by BARDA to conduct anthrax vaccine clinical trial

This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.

Pfizer and BioNTech submit application to USFDA for emergency use authorization of Omicron BA.4/BA.5-adapted bivalent vaccine booster for 5-11 year age

The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses

Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19

Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial

Ascletis Pharma completes patient enrollment in clinical for cure of HIV infection

The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.

Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics

He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets

AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData

Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials